Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03368963 · ClinicalTrials.gov registry record · Phase 1
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
A Phase 1 study of Gastric Adenocarcinoma and Metastatic Pancreatic Adenocarcinoma, sponsored by Emory University.
- Active
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 3
- Study locations
NCT03368963 is a Phase 1 study of Gastric Adenocarcinoma and Metastatic Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 64 participants, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03368963, a Phase 1 study of Gastric Adenocarcinoma and Metastatic Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions Studied
Interventions
- DRUG Trifluridine and Tipiracil Hydrochloride
- DRUG Nanoliposomal Irinotecan
Study Locations (3)
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2025-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03368963
The ClinicalTrials.gov registry entry for NCT03368963 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Trifluridine and Tipiracil Hydrochloride is the first listed.
NCT03368963 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03368963 about?
NCT03368963 is a clinical study titled "TAS102 in Combination With NAL-IRI in Advanced GI Cancers". This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by sur...
What is the current status of trial NCT03368963?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2018-01-30. Estimated completion is 2025-11-28.
What conditions does trial NCT03368963 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Colorectal Adenocarcinoma, Stage IV Pancreatic Cancer, Stage IV Gastric Cancer.
What interventions are being tested in trial NCT03368963?
The interventions under investigation include: Trifluridine and Tipiracil Hydrochloride (DRUG), Nanoliposomal Irinotecan (DRUG).
Who is sponsoring clinical trial NCT03368963?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03368963 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RECRUITING · Phase 1
-
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.